We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Tianlong Showcases Cutting-Edge Products and Innovative Molecular Diagnostic Solutions

By LabMedica International staff writers
Posted on 13 Nov 2023
Print article
Image: Tianlong’s cutting-edge products and innovative molecular diagnostic solutions are on display at MEDICA 2023 (Photo courtesy of Tianlong)
Image: Tianlong’s cutting-edge products and innovative molecular diagnostic solutions are on display at MEDICA 2023 (Photo courtesy of Tianlong)

Tianlong Science and Technology (Shaanxi, China) is showcasing its cutting-edge products and innovative molecular diagnostic solutions at MEDICA 2023. The company is also highlighting its classic integrated PCR lab solution and its brand new product - Panall 8000 All-in-One Molecular Diagnosis System at the show. The revolutionary Panall 8000 All-in-One Molecular Diagnosis System seamlessly integrates various diagnostic stages, setting new standards for efficiency and accuracy in the field of molecular diagnostics.

Tianlong is also exhibiting the RBT320 Agglutination Automated Detection System which is intended for the detection of Brucellosis based on the Rose Bengal Test (RBT) method. Designed for automating laboratory workflow, Tianlong RBT320 integrates various functions, including automatic sample loading, sample mixing, photographing, AI image recognition, and result interpretation. With optimized efficiency, RBT320 can process 320 samples per hour and is suitable for large-scale screening of Brucella antibodies. Tianlong RBT320 is highly automated and can empower labs with maximum efficiency and effectively avoid human errors, while the use of the RBT method can also be cost-effective for labs.

At MEDICA 2023, Tianlong is also presenting the iGeneCase 1600 Diagnostics-in-a-Suitcase, and PANA 9600X Automated Nucleic Acid Workstation, as well as a variety of products and compatible reagents. For instance, Tianlong's solution for nucleic acid detection of influenza virus is designed to identify and differentiate various strains, including Influenza A/B, Influenza C, Influenza A(H1&H3), Influenza A(H1N1), Influenza A(H3N2), and Influenza A(H5N1), as well as multiplex kit for Influenza A/B/Human Adenovirus/2019-nCoV. This comprehensive solution provides a scientific basis for accurate diagnosis and treatment of individuals with symptoms of influenza.

Related Links:
Tianlong Science and Technology

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.